ESMO in 30 Seconds is an online newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona. One of the highlights is the presentation of the GALAXIES Lung-201 study on an anti-TIGIT therapy. Roche received FDA approval for an injectable form of its PD-(L)1 inhibitor Tecentriq. AstraZeneca’s Capitello-290 study did not meet its primary endpoint in triple-negative breast cancer. ESMO also addressed the issue of burnout among oncology professionals. Researchers are testing Voranigo, a new brain cancer drug. Other abstracts released at the conference include breast cancer data from ApexOnco and early-stage bladder cancer trial data from Bicycle Therapeutics.
Source link
An ESMO Day 1 recap: All eyes on TIGIT
